Global Parenteral Nutrition Market, By Nutrition Type (Carbohydrates, Lipid Emulsion, Lipid Emulsion, Proteins, and Others (Amino acids, etc.)), By Patient Type (Infants, Adults, and Geriatric), By Application (Diabetes, Renal Failures, Obesity, Sarcopenia, Cancer, and Others (Digestive disorders, Metabolic Syndromes, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa). The global parenteral nutrition market was valued at US$ 4,548.7 Mn in 2023 and is expected to reach US$ 7,251 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6% from 2024 to 3031, as highlighted in a new report published by Coherent Market Insights.
The emerging prevalence of malnutrition among children is expected to bolster the growth of the global parenteral nutrition market. For instance, according to an article published by the World Health Organization, on June 9, 2021, globally, 1.9 billion adults are overweight or obese while 462 million adults are underweight. Moreover, according to the same source, globally, in 2020, it was reported that 149 million children, under the age of five, were estimated to be stunted, 45 million were estimated to be wasted, and 38.9 million were overweight or obese and around 45% of deaths among children, under the age of five years, occur mostly due to under nutrition.
Global Parenteral Nutrition Market- Drivers:
Increasing adoption of inorganic strategies such as product approval by regulatory authorities. For instance, in September 2020, Baxter, a global healthcare company, announced that the The U.S. Food and Drug Administration (FDA) approved Clinimix Injections and Clinimix E Injections formulations. It is easier to reach patient protein targets with the new Clinimix formulations as they contain up to 80 g/L of amino acids, the highest amount of protein in any multi-chamber bag currently available in the U.S. also contain less fluid and dextrose than previous formulations.
Global Parenteral Nutrition Market- Restraints:
The risk of complications associated with parenteral nutrition is a major factor restraining the growth of the global parenteral nutrition market. Parenteral nutrition, which involves delivering nutrients directly into the bloodstream through an intravenous line, carries inherent risks if not administered properly. Some common complications associated with parenteral nutrition include infections, blood clots, liver problems, and metabolic disturbances. These complications require additional treatment and lengthen hospital stays, increasing the cost of care.
Global Parenteral Nutrition Market- Opportunities:
Emerging markets in developing countries present promising growth opportunities for the global parenteral nutrition market. Rapidly developing healthcare infrastructure and rising income levels are expected to drive demand for advanced medical treatments in the emerging region. Countries such as India, China, Brazil and others in Southeast Asia and Latin America are experiencing significant economic development which is improving access to healthcare and expanding the middle class population. As public health programs are strengthened and more citizens gain health insurance coverage, lifesaving therapies such as parenteral nutrition will become progressively less of a luxury and more of a necessity. This in turn will facilitate wider acceptance and uptake of such medically prescribed nutrition support methods
Global Parenteral Nutrition Market Segmentation:
- The global parenteral nutrition market report is segmented into nutrition type, application, distribution channel, and region
- Based on the nutrition type, the market is segmented into carbohydrates, lipid emulsion, lipid emulsion, proteins, and others (amino acids, etc.),. Out of which, the lipid emulsion segment is expected to hold a dominant position in the global parenteral nutrition market during the forecast period, and this is attributed to the increasing product launches/approval.
- Based on the patient type, the market is segmented into infants, adults, and geriatric. Out of which, the infants segment is expected to hold a dominant position in the global parenteral nutrition market during the forecast period, and particularly preterm neonates or those with congenital gastrointestinal anomalies, often require parenteral nutrition as their digestive systems may not be fully developed or functional. Infants who are critically ill or those with failure to thrive may also require this support
- Based on the application, the market is segmented into diabetes, renal failures, obesity, sarcopenia, cancer, and others (digestive disorders, metabolic syndromes, etc.)). Out of which, the cancer segment is expected to hold a dominant position in the global parenteral nutrition market during the forecast period, and this is attributed increasing prevalence of cancer as Cancer and its treatments can lead to malnutrition due to decreased appetite, alterations in taste, difficulty swallowing, or gastrointestinal complications. PN can provide necessary nutrients when oral or enteral feeding is not possible, helping to prevent or treat malnutrition.
- Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period, and this is attributed to increasing number of hospital pharmacies
- Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Out of which, the North America segment is expected to dominate the market over the forecast period, and this is attributed to the increasing demand of parenteral nutrition in that region
Browse 44 Market Data Tables and 40 Figures spread through 180 Pages and in-depth TOC on Global Parenteral Nutrition Market, By Nutrition Type (Carbohydrates, Lipid Emulsion, Lipid Emulsion, Proteins, and Others (Amino acids, etc.)), By Patient Type (Infants, Adults, and Geriatric), By Application (Diabetes, Renal Failures, Obesity, Sarcopenia, Cancer, and Others (Digestive disorders, Metabolic Syndromes, etc.)), By Distribution Channel, (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Key Developments:
- In March 2022, Fresenius Kabi AG, a pharmaceutical company, announced that the U.S. Food and Drug Administration approved, an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in U.S. including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age. SMOFlipid can be used throughout the continuum of care from the hospital to home care settings.
- In November 2020, Otsuka Holdings Co., Ltd., a pharmaceutical company, announced the launch of ENEFLUID Injection, the amino acid, glucose, electrolyte, fat, and water-soluble vitamin injection. This ENEFLUID is the first peripheral parenteral nutrition solution in Japan that combines fat and water-soluble vitamins in addition to glucose, electrolytes, and amino acids in a dual-chamber bag. By compounding fat, more calories can be administered than the approved glucose, electrolyte, and amino acid infusions, and by compounding nine water-soluble vitamins
Link: https://www.coherentmarketinsights.com/market-insight/parenteral-nutrition-market-4804
Key Takeaways of the Global Parenteral Nutrition Market:
- The global parenteral nutrition market is expected to exhibit a CAGR of 6% during the forecast period.
- Among regions, North America is expected to be the dominant region in the global parenteral nutrition market due to increasing product approval by regulatory authority. For instance, in March 2022, Fresenius Kabi AG, a pharmaceutical company, announced that it had received an approval from the U.S. Food and Drug Administration, SMOFlipid lipid injectable emulsion for pediatric patients requiring parenteral nutrition
- Major players operating in the global parenteral nutrition market include AbbVie Inc., Danone, Fresenius Kabi AG, GENTAG, Inc., GSK plc., Nestlé SA, Nutricia, Sun Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, Otsuka Holdings Co., Ltd., and Otsuka Holdings Co., Ltd.
